Five-Year Survival of Patients (pts) from Transcend NHL 001 (TRANSCEND) Supports Curative Potential of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Jeremy S. Abramson, Maria Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon E. Arnason, Manali Kamdar, David G. Maloney, Mazyar Shadman, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Juliana E. Hidalgo-López, Jing Wang, Ken Ogasawara, Ashvin Singh, Tanya Siddiqi
Institutions: Harvard University, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Nebraska Medical Center, University of Nebraska Medical Center, The University of Texas MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, University of Colorado Cancer Center, University of Washington, Fred Hutch Cancer Center, University of California, San Francisco, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Northside Hospital, Levine Cancer Institute, Bristol-Myers Squibb (United States), City Of Hope National Medical Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405040645